With a significant amount of dry powder, private equity firms can influence how research happens and where therapies are deployed—and how quickly, says BCG’s Bob Lavoie.
- Medical Devices and Technology
- Principal Investors and Private Equity
- Health Care Industry
- Health Care Payers, Providers, Systems & Services
- Corporate Finance and Strategy
- Mergers and Acquisitions
- Marketing and Sales
- Post-Merger Integration
- Innovation Strategy and Delivery
- Corporate Finance and Strategy
Education
- MBA, Rotman School of Business, University of Toronto
Honors and Awards
- Board of Directors, The Parent-Child Home Program
Bob Lavoie is a core member of the Health Care and Principal Investors & Private Equity practices at Boston Consulting Group, where he focuses on medtech, diagnostics, and tools. Bob has been advising clients for more than 18 years on strategic, commercial, business model innovation, and transaction support matters. Bob is committed to delivering pragmatic and value-creating results for his clients.
Recently Bob has also focused on helping clients adapt to the changing health care environment that includes consolidation, value-based care, and the shift to solutions.
Bob’s work experience covers the medtech landscape, including procedure-based devices, drug delivery, and diagnostic systems and tools. He has worked with clients across all major therapeutic areas of focus, including but not limited to vascular, orthopedics, oncology, and neurology. He has also completed more than 100 diligence efforts for strategic and financial investors.
Before he joined the firm, Bob was a senior partner and managing director leading L.E.K.’s New York office and global medtech practice. He is a frequent speaker at industry conferences and contributor to industry publications on the subjects of medtech trends and provider landscape evolution.
